Rubrik: Aktuelle Epidemiologie und Diagnostik in der Mikrobiologie
Nimmt mit 50 Jahren nochmal richtig Fahrt auf: Parvovirus B19 (S. 26)
1. Cossart YE, Field AM, Cant B, Widdows D. Parvovirus-like particles in human sera. Lancet 1975; 1 (7898): 72-3. doi: 10.1016/s0140-6736(75)91074-0.
2. Yamano H, Nakade T, Ogawa H, Matsukura H, Okubo Y, Yamaguchi H, Okochi K. An unidentified antigen-antibody system, Nakatani, detected by immunoelectro syneresis. Blood Programme 1980; 3: 275-279.
3. Okochi K, Mori R, Miyazaki M, Cohen BJ, Mortimer PP. Nakatani antigen and human parvovirus (B19). Lancet. 1984; 1 (8369): 160-161. doi: 10.1016/s0140-6736(84)90087-4.
4. Reno ML, Cox CR, Powell EA. Parvovirus B19: a clinical and diagnostic review. Clin Microbiol Newsl 2022; 44 (12): 107-114. doi: 10.1016/j.clinmicnews.2022.06.00.
5. Yu MY, Alter HJ, Virata-Theimer ML, Geng Y, Ma L, Schechterly CA, Colvin CA, Luban NL. Parvovirus B19 infection transmitted by transfusion of red blood cells confirmed by molecular analysis of linked donor and recipient samples. Transfusion 2010; 50 (8): 1712-1721. doi: 10.1111/j.1537-2995.2010.02591.x.
6. Arbeitskreis Blut des Bundesministeriums für Gesundheit. Parvovirus B19. Bundesgesundheitsbl 2010, 53: 944-956. doi: 10.1007/s00103-010-1109-9.
7. Farahmand M, Tavakoli A, Ghorbani S, Monavari SH, Kiani SJ, Minaeian S. Molecular and serological markers of human parvovirus B19 infection in blood donors: A systematic review and meta-analysis. Asian J Transfus Sci 2021; 15 (2): 212-222. doi: 10.4103/ajts.ajts_185_20.
8. Röhrer C, Gärtner B, Sauerbrei A, Böhm S, Hottenträger B, Raab U, Thierfelder W, Wutzler P, Modrow S. Seroprevalence of parvovirus B19 in the German population. Epidemiol Infect 2008; 136 (11): 1564-1575. doi: 10.1017/S0950268807009958.
9. Reinheimer C, Allwinn R, Doerr HW, Wittek M. Seroepidemiology of parvovirus B19 in the Frankfurt am Main area, Germany: evaluation of risk factors. Infection 2010; 38 (5): 381-385. doi: 10.1007/s15010-010-0035-y.
10. Heegaard ED, Brown KE. Human parvovirus B19. Clin Microbiol Rev 2002; 15 (3): 485-505. doi: 10.1128/CMR.15.3.485-505.2002
11. Landry ML. Parvovirus B19. Microbiol Spectr 2016; 4 (3). doi: 10.1128/microbiolspec.DMIH2-0008-2015. PMID: 27337440.
12. Bascietto F, Liberati M, Murgano D, Buca D, Iacovelli A, Flacco ME, Manzoli L, Familiari A, Scambia G, D'Antonio F. Outcome of fetuses with congenital parvovirus B19 infection: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2018; 52 (5): 569-576. doi: 10.1002/uog.19092.
13. Beck R, Exler S, Enders M. Parvovirus B19-Infektion und Schwangerschaft. Epid Bull 2024; 24: 3-7. doi: 10.25646/12157.
14. Robert Koch Institut (RKI). https://survstat.rki.de/Content/Query/Create.aspx
15. European Center for Disease and Control (ECDC). Increase in parvovirus B19 detections – multi-country – 2024. Wkly Bull 16. 14.-20.04.2024. https://www.ecdc.europa.eu/sites/default/files/documents/communicable-disease-threats-report-week-16-2024_final.pdf
16. European Center for Disease and Control (ECDC). Risks posed by reported increased circulation of human parvovirus B19 in the EU/EEA. Threat Assessment Brief. 05.06.2024. https://www.ecdc.europa.eu/en/publications-data/risks-posed-reported-increased-circulation-human-parvovirus-b19-eueea
17. d'Humières C, Fouillet A, Verdurme L, Lakoussan SB, Gallien Y, Coignard C, Hervo M, Ebel A, Soares A, Visseaux B, Maire B, Juan PH, Parent du Châtelet I, Guthmann JP, Durand J. An unusual outbreak of parvovirus B19 infections, France, 2023 to 2024. Euro Surveill 2024; 29 (25): 2400339. doi: 10.2807/1560-7917.ES.2024.29.25.2400339.
18. Nordholm AC, Trier Møller F, Fischer Ravn S, Flink Sørensen L, Moltke-Prehn A, Elskær Mollerup J, Funk T, Sperling L, Jeyaratnam U, Træholt Franck K, Hjort-Pedersen K, Hjørnet Kamper C, Thoft Nielsen R, Jokelainen P, Wessman M. Epidemic of parvovirus B19 and disease severity in pregnant people, Denmark, January to March 2024. Euro Surveill 2024; 29 (24): 2400299. doi: 10.2807/1560-7917.ES.2024.29.24.2400299.
19. Patalon T, Saciuk Y, Trotzky D, Pachys G, Ben-Tov A, Segal Y, Gazit S. An Outbreak of Parvovirus B19 in Israel. Viruses 2023; 15 (11): 2261. doi: 10.3390/v15112261.
20. Fourgeaud J, Allali S, Toubiana J, Pinhas Y, Frange P, Leruez-Ville M, Cohen JF. Post-COVID-19 pandemic outbreak of severe Parvovirus B19 primary infections in Paris, France: 10-year interrupted time-series analysis (2012-2023). J Clin Virol 2023; 167: 105576. doi: 10.1016/j.jcv.2023.105576.
21. Guillet M, Bas A, Lacoste M, Ricard C, Visse C, Barlet V, Malard L, Le Cam S, Morel P, de Lamballerie X, Laperche S, Gallian P. New atypical epidemiological profile of parvovirus B19 revealed by molecular screening of blood donations, France, winter 2023/24. Euro Surveill 2024; 29 (21): 2400253. doi: 10.2807/1560-7917.ES.2024.29.21.2400253.
22. Russcher A, van Boven M, Benincà E, Verweij EJTJ, Molenaar-de Backer MWA, Zaaijer HL, Vossen ACTM, Kroes ACM. Changing epidemiology of parvovirus B19 in the Netherlands since 1990, including its re-emergence after the COVID-19 pandemic. Sci Rep 2024; 14 (1): 9630. doi: 10.1038/s41598-024-59582-7.
23. Drews SJ, Charlton C, O'Brien SF, Burugu S, Denomme GA. Decreasing parvovirus B19 and hepatitis A nucleic acid test positivity rates in Canadian plasma donors following the initiation of COVID-19 restriction in March 2020. Vox Sang 2024; 119 (6): 624-629. doi: 10.1111/vox.13616.
24. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V. (AWMF). Labordiagnostik schwangerschaftsrelevanter Virusinfektionen: S2k-Leitlinie Registernummer 093/001. https://register.awmf.org/assets/guidelines/093-001l_S2k_Labordiagnostik-schwangerschaftsrelevanter-Virusinfektionen_2022-02.pdf
25. https://www.labor-enders.de/konsiliarlabor-parvoviren/
Bakterien-Husten nach Virus-Husten: Die Renaissance der Pertussis (S. 26)
1. Gordon JE, Hood RI. Whooping cough and its epidemiological anomalies. Am J Med Sci 1951; 222 (3): 333-361. doi: 10.1097/00000441-195109000-00011.
2. Zatovkaňuková P, Slíva J. The potential dangers of whooping cough: a case of rib fracture and pneumothorax. BMC Infect Dis 2024; 24 (1): 1293. doi: 10.1186/s12879-024-10192-8.
3. Robert-Koch Institut (RKI). https://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_Pertussis.html
4. Bordet JJBV, Gengou OPV. Le Microbe de la coqueluche. An Inst Pasteur 1906; 20: 731-741.
5. Gregg KA, Merkel TJ. Pertussis Toxin: A Key Component in Pertussis Vaccines? Toxins (Basel) 2019; 11 (10): 557. doi: 10.3390/toxins11100557.
6. Goldsmith JA, Nguyen AW, Wilen RE, Wijagkanalan W, McLellan JS, Maynard JA. Structural basis for antibody neutralization of pertussis toxin. bioRxiv 2024 Sep 23:2024.09.23.614357. doi: 10.1101/2024.09.23.614357.
7. Hellenbrand W, Wichmann O, Liese J, Heininger U, Wirsing v König CH, Riffelmann M, Terhardt M, Fink E, Kümmel C, Schöneberger K, Schroeder S: Workshop Bericht – Drei Jahre bundesweite Keuchhusten-Meldepflicht: Erfahrungsaustausch zwischen ÖGD, Ärzteschaft und beteiligten Laboren zur Identifizierung von Maßnahmen zur Verbesserung der Surveillance. Epid Bull 2017; 21: 187-197. doi: 10.17886/EpiBull-2017-029.
8. Perkins TA, Tran QM. Timing is everything when it comes to pertussis vaccination. Lancet Infect Dis 2022; 22 (2): 158-159. doi: 10.1016/S1473-3099(21)00353-4.
9. Ständige Impfkommission. Empfehlungen der Ständigen Impfkommission (STIKO) beim Robert Koch-Institut 2024. Epid Bull 2024; 4: 1-72 doi: 10.25646/11892.4.
10. Eidgenössischen Kommission für Impffragen. https://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-b/richtlinien-empfehlungen/allgemeine-empfehlungen/schweizerischer-impfplan.pdf.download.pdf/schweizerischer-impfplan-de.pdf.
11. Nationales Impfgremium Österreich. https://www.sozialministerium.at/impfplan.
12. Robert-Koch Institut (RKI). https://survstat.rki.de/Content/Query/Create.aspx.
13. Bagcchi S. Pertussis cases rise in Denmark. Lancet Infect Dis 2023; 23 (11): e469. doi: 10.1016/S1473-3099(23)00645-X.
14. Venkatesan P. Whooping cough cases rising. Lancet Respir Med 2024; 12 (8) :e50. doi: 10.1016/S2213-2600(24)00204-2.
15. Wise J. Whooping cough: What's behind the rise in cases and deaths in England? BMJ 2024; 385: q1118. doi: 10.1136/bmj.q1118.
16. Holt E. Pertussis outbreak in Czech Republic. Lancet Infect Dis 2024; 24 (6): e359. doi: 10.1016/S1473-3099(24)00291-3.
17. Hu Y, Guo M, Yao K. Infections in preschool and school-aged children are driving the recent rise in pertussis in China. J Infect 2024; 88 (6): 106170. doi: 10.1016/j.jinf.2024.106170.
18. Tanne JH. Whooping cough: Fivefold rise in US cases spells return to pre-pandemic levels. BMJ 2024; 386: q2114. doi: 10.1136/bmj.q2114.
19. Statista GmbH. https://de.statista.com/statistik/daten/studie/77595/umfrage/impfquote-gegen-diphtherie-tetanus-und-pertussis-bei-kindern-in-deutschland/
20. Witte J, Zeitler A, Diekmanshemke, Hasemann L. DAK-Kinder- und Jugendreport 2022. https://www.dak.de/dak/download/dak-kinder--und-jugendreport-2022-pdf-2584960.pdf.
21. Böhmer MM, Hellenbrand W, Matysiak-Klose D, Heininger U, Müters S, Wichmann O. Pertussis vaccination coverage among adults in Germany. Dtsch Med Wochenschr. 2013; 138 (28-29): 1451-1457. doi: 10.1055/s-0033-1343249.
22. Hohlbaum K. Pertussis: Viel zu niedrige Impfquoten bei Erwachsenen. Dtsch Arztebl 2013; 110 (38): A-1710 / B-1514 / C-1490.
23. Saxena K, Marden JR, Carias C, Bhatti A, Patterson-Lomba O, Gomez-Lievano A, Yao L, Chen YT. Impact of the COVID-19 pandemic on adolescent vaccinations: projected time to reverse deficits in routine adolescent vaccination in the United States. Curr Med Res Opin 2021; 37 (12): 2077-2087. doi: 10.1080/03007995.2021.1981842.
24. Saitoh A, Okabe N. Changes and remaining challenges for the Japanese immunization program: Closing the vaccine gap. Vaccine 2021; 39 (22): 3018-3024. doi: 10.1016/j.vaccine.2021.04.023.
25. Prasad N, Turner N, Alexander S. Early childhood education staff are falling through a vaccination policy gap in New Zealand. N Z Med J 2022; 135 (1548): 96-102.
26. Evans B, Keiser O, Kaiser L, Jombart T. Analysis of global routine immunisation coverage shows disruption and stagnation during the first two-years of the COVID-19 pandemic with tentative recovery in 2022. Vaccine X 2023; 15: 100383. doi: 10.1016/j.jvacx.2023.100383.
27. Cohen R, Ashman M, Taha MK, Varon E, Angoulvant F, Levy C, Rybak A, Ouldali N, Guiso N, Grimprel E. Pediatric Infectious Disease Group (GPIP) position paper on the immune debt of the COVID-19 pandemic in childhood, how can we fill the immunity gap? Infect Dis Now 2021; 51 (5): 418-423. doi: 10.1016/j.idnow.2021.05.004.
28. McIntyre PB, Best E, Byrnes CA, Sinclair O, Trenholme A, Grant CC. Pertussis deaths in New Zealand without community transmission-an infant immunity gap? Lancet Reg Health West Pac 2023; 37: 100850. doi: 10.1016/j.lanwpc.2023.100850.
29. Martinón-Torres F, Heininger U, Thomson A, Wirsing von König CH. Controlling pertussis: how can we do it? A focus on immunization. Expert Rev Vaccines 2018; 17 (4): 289-297. doi: 10.1080/14760584.2018.1445530.
30. Schielke A, Takla A, von Kries R, Wichmann O, Hellenbrand W. Marked Underreporting of Pertussis Requiring Hospitalization in Infants as Estimated by Capture-Recapture Methodology, Germany, 2013-2015. Pediatr Infect Dis J 2018; 37 (2): 119-125. doi: 10.1097/INF.0000000000001698.
31. MacIntyre CR, de Sousa JC, Heininger U, Kardos P, Konstantopoulos A, Middleton D, Nolan T, Papi A, Rendon A, Rizzo A, Sampson K, Sette A, Sobczyk E, Tan T, Weil-Olivier C, Weinberger B, Wilkinson T, von König CHW. Public health management of pertussis in adults: Practical challenges and future strategies. Hum Vaccin Immunother 2024; 20 (1): 2377904. doi: 10.1080/21645515.2024.2377904.
32. Guiso N, Wirsing von König CH. Surveillance of pertussis: methods and implementation. Expert Rev Anti Infect Ther 2016; 14 (7): 657-667. doi: 10.1080/14787210.2016.1190272.
33. Bethke N, Gellert P, Knoll N, Weber N, Seybold J. A school-based educational on-site vaccination intervention for adolescents in an urban area in Germany: feasibility and psychometric properties of instruments in a pilot study. BMC Public Health 2022; 22 (1): 60. doi: 10.1186/s12889-021-12443-8.
34. Pluijmaekers AJM, Steens A, Houweling H, Rots NY, Benschop KSM, van Binnendijk RS, Bodewes R, Brouwer JGM, Buisman A, Duizer E, van Els CACM, Hament JM, den Hartog G, Kaaijk P, Kerkhof K, King AJ, van der Klis FRM, Korthals Altes H, van der Maas NAT, van Meijeren DL, Middeldorp M, Rijnbende-Geraerts SD, Sanders EAM, Veldhuijzen IK, Vlaanderen E, Voordouw ACG, Vos ERA, de Wit J, Woudenberg T, van Vliet JA, de Melker HE. A literature review and evidence-based evaluation of the Dutch national immunisation schedule yield possibilities for improvements. Vaccine X. 2024; 20: 100556. doi: 10.1016/j.jvacx.2024.100556.
35. Galeas-Pena M, Hirsch A, Kuang E, Hoffmann J, Gellings P, Brown JB, Limbert VM, Callahan CL, McLachlan JB, Morici LA. A novel outer membrane vesicle adjuvant improves vaccine protection against Bordetella pertussis. NPJ Vaccines. 2024; 9 (1): 190. doi: 10.1038/s41541-024-00990-1.
36. Tan C, Xiao Y, Chen S, Liu T, Zhou J, Zhang S, Hu Y, Zhou J, She Z, Tian B, Wu A, Li C. Bibliometrics analysis and knowledge mapping of pertussis vaccine research: trends from 1994 to 2023. Infection. 2024; 53 (3): 1001-1012. doi: 10.1007/s15010-024-02414-7.
37. Monterrubio-López GP, Llamas-Monroy JL, Martínez-Gómez ÁA, Delgadillo-Gutiérrez K. Novel vaccine candidates of Bordetella pertussis identified by reverse vaccinology. Biologicals 2024; 85: 101740. doi: 10.1016/j.biologicals.2023.101740.
38. Ernst K. Novel strategies to inhibit Pertussis toxin. Toxins (Basel) 2022; 14 (3): 187. doi: 10.3390/toxins14030187.
39. Lietz S, Sommer A, Sokolowski LM, Kling C, Rodriguez Alfonso AA, Preising N, Alpízar-Pedraza D, King J, Streit L, Schröppel B, van Erp R, Barth E, Schneider M, Münch J, Michaelis J, Ständker L, Wiese S, Barth H, Pulliainen AT, Scanlon K, Ernst K. Alpha-1 antitrypsin inhibits pertussis toxin. J Biol Chem 2024; 300 (12): 107950. doi: 10.1016/j.jbc.2024.107950.
40. Pyles GM, Huckaby AB, Gutierrez MdlP, Witt WT, Mateu-Borrás M, Dublin SR, Rocuskie-Marker C, Sesti BN, Peasak K, Bitzer GJ, Rader N, Weaver KL, Boehm DT, Fitzgerald N, Chapman J, Ulicny S, Damron FH, Barbier M. Virus-like particles displaying the mature C-terminal domain of filamentous hemagglutinin are immunogenic and protective against Bordetella pertussis respiratory infection in mice. Infect Immun 2024; 92 (8): e0027024. doi: 10.1128/iai.00270-24.
Rubrik: Antimikrobielle Resistenzen
Globale Entwicklung antimikrobieller Resistenzen – ein Update (S. 28)
1. Murray, Christopher J L et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 2022; 399(10325): 629 – 655. doi: 10.1016/S0140-6736(21)02724-0
2. Naghavi, Mohsen et al. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. Lancet 2024; 404(10459): 1199 – 1226. doi: 10.1016/S0140-6736(24)01867-1
3. World Health Organization (WHO). WHO Bacterial Priority Pathogens List, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. published online May 17, 2024. https://iris.who.int/bitstream/handle/10665/376776/9789240093461-eng.pdf?sequence=1 [11.03.2025]
4. Robert Koch Institut (RKI). Staphylokokken-Erkrankungen, insbesondere Infektionen durch MRSA. RKI-Ratgeber. Stand 17.01.2025. https://www.rki.de/DE/Aktuelles/Publikationen/RKI-Ratgeber/Ratgeber/Ratgeber_Staphylokokken_MRSA.html?nn=16906848#doc16804810bodyText14 [11.03.2025]
5. World Health Organization (WHO). Estimating the impact of vaccines in reducing antimicrobial resistance and antibiotic use. published online Oct 10, 2024. https://iris.who.int/bitstream/handle/10665/379116/9789240098787-eng.pdf?sequence=1 [12.03.2025]
6. Chaw, Pa Saidou et al. Knowledge, attitude and practice of Gambian health practitioners towards antibiotic prescribing and microbiological testing: a cross-sectional survey. Trans R Soc Trop Med Hyg 2017; 111(3):117-124. doi: 10.1093/trstmh/trx027
Rubrik: Chikungunya-Virus
Chikungunya – neue Präventionsmöglichkeiten durch aktive Immunisierung (S. 31)
1. European Centre for Disease Prevention and Control (ECDC). Chikungunya virus disease. https://www.ecdc.europa.eu/en/chikungunya-virus-disease [03.06.2025]
2. Liu, Q et al. Chikungunya virus in Europe: A retrospective epidemiology study from 2007 to 2023. PLoS Negl Trop Dis 2025; 19(3):e0012904. doi: 10.1371/journal.pntd.0012904
3. Tiozzo, G et al. Assessing chikungunya’s economic burden and impact on health-related quality of life: Two systematic literature reviews. PLoS Negl Trop Dis 19(5): e0012990. doi: 10.1371/journal.pntd.0012990
4. Tavares, WG et al. Chikungunya fever in hospitalized children and adolescents: clinical and epidemiological aspects in a region of northeastern Brazil. J Pediatr (Rio J) 2025;101(3):466-472. doi: 10.1016/j.jped.2025.01.010
5. Micheleto, JPC et al. Risk factors for mortality in patients with chikungunya: A systematic review and meta-analysis. Trop Med Int Health 2025; 30(4): 235-245. doi: 10.1111/tmi.14088
6. European Centre for Disease Prevention and Control (ECDC). Chikungunya worldwide overview - Situation update, March 2025. https://www.ecdc.europa.eu/en/chikungunya-monthly [03.06.2025]
7. Schneider, M et al. Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2023; 401(10394): 2138–2147. doi: 10.1016/S0140-6736(23)00641-4
8. Ixchiq – Zusammenfassung der Merkmale des Arzneimittels, Stand 23.05.2025. https://www.ema.europa.eu/de/documents/product-information/ixchiq-epar-product-information_de.pdf
9. Rote-Hand-Brief: Ixchiq (Chikungunya-Impfstoff): Neue Kontraindikation bei Patienten ab 65 Jahren, während die EU-weite Überprüfung läuft. Stand 22.05.2025. https://www.pei.de/SharedDocs/Downloads/DE/newsroom/veroeffentlichungen-arzneimittel/rhb/25-05-22-rhb-ixchiq-chikungunya-impfstoff.pdf?__blob=publicationFile&v=2#:~:text=Ixchiq%20ist%20seit%20dem%2028,abgeschwächtes%20CHIKV%20des%20Stamms%20Δ5nsP3.
10. European Medicines Agency (EMA). EMA starts review of Ixchiq (live attenuated chikungunya vaccine). published online May 7, 2025. https://www.ema.europa.eu/en/news/ema-starts-review-ixchiq-live-attenuated-chikungunya-vaccine [04.06.2025]
11. U.S. Food & Drug Administration (FDA). FDA and CDC Recommend Pause in Use of Ixchiq (Chikungunya Vaccine, Live) in Individuals 60 Years of Age and Older While Postmarketing Safety Reports are Investigated. published online May 9, 2025. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-and-cdc-recommend-pause-use-ixchiq-chikungunya-vaccine-live-individuals-60-years-age-and-older [07.06.2025]
12. Buerger, V et al. Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents. Lancet Infect Dis 2025; 25(1): 114–125. doi: 10.1016/S1473-3099(24)00458-4
13. Vimkunya – Zusammenfassung der Merkmale des Arzneimittels, Stand 24.03.2025. https://www.ema.europa.eu/de/documents/product-information/vimkunya-epar-product-information_de.pdf
14. Richardson, JS et al. Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2025; 405(10487):1343-1352. doi: 10.1016/S0140-6736(25)00345-9
15. Bachmann, MF et al. Virus-like particles: a versatile and effective vaccine platform. Expert Rev Vaccines 2025; 24(1): 444-456. doi: 10.1080/14760584.2025.2508517
16. Tindale, LC et al. Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2025; 405(10487):1353-1361. doi: 10.1016/S0140- 6736(25)00372-1
